Brief: Shanghai Fosun Pharma Receives Approval From China's NMPA For Clinical Trial Of DM1001 Formulation
24/07/2026 11:21
BRIEF-Shanghai Fosun Pharma Receives Approval From China's NMPA For Clinical Trial Of DM1001 Formulation July 24 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:
APPROVAL FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR CLINICAL TRIAL OF DM1001 FORMULATION
Further company coverage: 600196.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Fosun Pharmaceutical
See all newsSHH Margin Trading -- Fosun Pharma Margin Long Amount is 1,592 (x10000) yuan, Short Selling Volume is 5 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,031 (x10000) yuan, Short Selling Volume is 1 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,109 (x10000) yuan, Short Selling Volume is 10 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 2,131 (x10000) yuan, Short Selling Volume is 0.21 (x10000) shares
SHH Margin Trading -- Fosun Pharma Margin Long Amount is 1,865 (x10000) yuan, Short Selling Volume is 0.15 (x10000) shares